Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Safimaltib |
| Synonyms | |
| Therapy Description |
Safimaltib is an inhibitor that blocks the activity of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), resulting in decreased NF-kappaB and JAK/STAT signaling, potentially leading to increased apoptosis and decreased growth of MALT1-expressing tumor cells (PMID: 39894894, NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Safimaltib | JNJ67856633|JNJ 67856633|JNJ-67856633 | MALT1 Inhibitor 6 | Safimaltib is an inhibitor that blocks the activity of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), resulting in decreased NF-kappaB and JAK/STAT signaling, potentially leading to increased apoptosis and decreased growth of MALT1-expressing tumor cells (PMID: 39894894, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03900598 | Phase I | Safimaltib | A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Completed | USA | ITA | ISR | GRC | GBR | FRA | ESP | DEU | AUS | 3 |